K-Bio Pharma's $100B AI Gamble: How Samsung Biologics and Celltrion Are Betting Everything on AI Drug Discovery

South Korea's bio-pharma giants are racing to combine world-class manufacturing with AI drug discovery. From Samsung Biologics' million-liter mega-plants to Celltrion's 13-drug pipeline and startups like Standigm finding candidates in 7 months instead of years — this is K-Bio's boldest bet yet.